Upstream processing is the first half of biopharmaceutical manufacturing. It covers everything involved in growing cells and getting them to produce a target molecule, from developing the right cell line to expanding those cells in large bioreactors and finally harvesting the product. Once the cells have done their job and the desired protein or enzyme is collected from the growth medium, downstream processing takes over to purify it. The dividing line between the two is the harvest step.
What Upstream Processing Actually Involves
Think of upstream processing as a sequence of increasingly larger steps, each building on the last. It starts with identifying and engineering the right organism to produce the molecule you want, then feeding and growing that organism under tightly controlled conditions, and ends with collecting the raw product from the cell culture.
The major stages, in order, are:
- Cell line development: Scientists isolate a microorganism or select a mammalian cell capable of producing the target protein. They then make genetic modifications to improve how much product the cell makes and how stable it is. These modified genes are typically inserted into host organisms that are well-characterized and safe to work with.
- Media preparation: Cells need a carefully formulated liquid environment to grow in. This growth medium supplies amino acids, vitamins, inorganic salts, and a carbon source like glucose. Many formulations also include hormones and growth factors. Historically, animal serum was added to support growth, but modern manufacturing increasingly uses serum-free media, which gives manufacturers more control over exactly what the cells are exposed to.
- Inoculum expansion: A small number of cells from a frozen stock are gradually grown in larger and larger vessels, from flasks to small bioreactors, until there are enough to seed a production-scale bioreactor. This step can take days to weeks depending on the cell type.
- Production bioreactor culture: The expanded cells are transferred into the final large-scale bioreactor, where they grow and produce the target molecule over a defined period. For monoclonal antibodies grown in mammalian cells, a typical production run lasts 7 to 14 days and yields a product concentration of 1 to 5 grams per liter.
- Harvest and clarification: Once the culture is complete, the product must be separated from the cells and cell debris. This is the boundary where upstream ends and downstream begins.
Mammalian Cells vs. Microbial Systems
Not all upstream processes look the same. The choice of production organism shapes nearly every decision that follows, and the two main categories are mammalian cell culture and microbial fermentation.
Mammalian cells, most commonly Chinese hamster ovary (CHO) cells, are the standard for producing antibodies and other large, complex proteins. These proteins need specific chemical modifications after they’re assembled, modifications that only mammalian cells can reliably perform. The tradeoff is cost and time: mammalian cultures grow slowly, require delicate conditions, and are expensive to maintain.
Microbial systems like bacteria offer the opposite profile. They grow fast, produce high yields, and are cheaper to work with. They’re the preferred choice for smaller biological molecules, including antibody fragments and peptide-based drugs. Development timelines are shorter, filtration is simpler, and batch-to-batch consistency tends to be better. But microbes can’t make the complex modifications that large therapeutic proteins require, so they aren’t suitable for full-sized antibodies.
The Bioreactor: Where Production Happens
The bioreactor is the centerpiece of upstream processing. Its job is deceptively simple: keep cells alive, healthy, and productive. In practice, that means precisely controlling temperature, acidity, dissolved oxygen levels, and nutrient delivery throughout the entire culture period.
The most common design in large-scale manufacturing is the stirred-tank bioreactor, which uses an impeller to keep the culture mixed and ensure oxygen reaches every cell. Single-use (disposable) bioreactors have gained popularity because they eliminate the need for cleaning and sterilization between batches, reducing turnaround time and the risk of contamination. Wave-type bioreactors, which rock a flexible bag to create gentle mixing, are often used at smaller scales or for cell expansion steps.
Two of the most critical performance characteristics when running a bioreactor are mixing (keeping the solution uniform so no cell sits in a pocket of depleted nutrients) and mass transfer (getting enough oxygen in and excess carbon dioxide out). Engineers quantify oxygen delivery using a measurement called the oxygen mass transfer coefficient. Keeping this value consistent is one of the primary strategies for scaling up from a small laboratory bioreactor to an industrial one holding thousands of liters.
Scaling Up From Lab to Factory
A process that works perfectly in a 2-liter flask won’t automatically perform the same way in a 2,000-liter production vessel. Scaling up is one of the most challenging aspects of upstream processing because the physics of mixing and gas exchange change with volume.
Engineers typically maintain geometric similarity between small and large bioreactors, meaning the proportions of the vessel stay the same even as it gets bigger. They then try to hold key engineering parameters constant, particularly the power input per unit volume (how vigorously the liquid is stirred) and the speed at which gas bubbles rise through the culture. When those two factors are matched, oxygen delivery to the cells stays roughly equivalent across scales. This straightforward approach has proven effective in many real-world scale-ups, though fine-tuning is almost always necessary.
Harvest: The Final Upstream Step
After the culture period ends, the target molecule is dissolved in a complex soup of cells, cell fragments, DNA, and spent nutrients. The harvest step separates the product from this mixture, producing a clarified liquid that downstream teams can then purify.
Several technologies handle this separation. Disc-stack centrifuges spin the culture at high speed, using stacked conical discs to push whole cells and large debris to the outside while the product-containing liquid flows through. Depth filtration passes the culture through layers of fiber that trap cells and particles, offering low cost, fast processing, and minimal damage to the product. Tangential-flow filtration (TFF) runs the liquid across a membrane rather than straight through it, which prevents clogging and works well for very large batches. Many facilities combine methods, using centrifugation first to remove the bulk of cells and then depth filtration or TFF to polish the result.
For large-scale production, TFF and centrifuge-plus-depth-filtration are the most common combinations. The choice depends on batch size, product sensitivity, and facility constraints.
Batch vs. Continuous Processing
Traditional upstream processing runs in batch mode: you seed a bioreactor, grow cells for one to two weeks, harvest everything, clean the vessel, and start over. This approach is well understood and regulatory agencies are very familiar with it, but it ties up expensive equipment for long stretches.
Continuous and intensified processing methods are changing that picture. By constantly feeding fresh media and removing spent culture, or by running smaller bioreactors at higher cell densities, manufacturers can increase space-time yields up to tenfold, shorten production campaigns by around 30%, and save significant time during the cell expansion phase. These gains come from keeping cells in their most productive state for longer and using equipment more efficiently. The shift toward continuous upstream processing is especially prominent in monoclonal antibody manufacturing, where even modest productivity gains translate to meaningful cost savings given the enormous market demand for these drugs.